A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis.
Ejskjaer N, Wo JM, Esfandyari T, Mazen Jamal M, Dimcevski G, Tarnow L, Malik RA, Hellström PM, Mondou E, Quinn J, Rousseau F, McCallum RW.
Ejskjaer N, et al. Among authors: wo jm.
Neurogastroenterol Motil. 2013 Feb;25(2):e140-50. doi: 10.1111/nmo.12064. Epub 2012 Dec 23.
Neurogastroenterol Motil. 2013.
PMID: 23279217
Clinical Trial.